We develop innovative hi-tech therapeutic applications for interventional medicine. Our main product is EchoLaser: the first and unique integrated Laser-Ultrasound system that allows for the diagnosis and micro-invasive treatment of benign and malignant tumours. EchoLaser uses the laser radiation transmitted by independent sources (up to 4) through extremely thin optical fibres (0,3 mm) inserted percutaneously under a proprietary ultrasound guiding system (which includes a planning and simulation software). EchoLaser Therapy can induce a cytoreduction process on benign lesions (e.g.: BPH, thyroid nodules) or destroy cancerous tissue of malignant lesions (e.g.: low-risk localized prostate and kidney cancer, etc.). No general anesthesia is generally required. Procedures can be performed in an outpatient regimen, with consequent faster recovery after treatment.
We want to play an important role in the new frontier of Precision Medicine, which is more than genomics and bespoke pharmacological treatment, but includes more accurate imaging and non surgical treatments (e.g. ablation).
The core EchoLaser Therapy treatments are:
ModìLite – neck lesions, such as benign thyroid nodules and metastatic lymph nodes.
SoracteLite – urinary system disorders like Benign Prostatic Hyperplasia (BPH) or low-risk localized prostate and kidney cancer. SoracteLite is the first and only laser treatment for BPH performed with a trans-perineal approach (reducing the complications of the traditional trans-urethral approach).
PBLite – treatment of primary and secondary malignant liver tumours through percutaneous insertion of optical fibres.
Company’s Keywords:
<15
<6453000
<2008
Your request has been submitted successfully.
Own or work here?